Clinical evaluation of cefotaxime in the treatment of purulent meningitis in children.
D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D002439:Cefotaxime / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D008581:Meningitis / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002439:Cefotaxime